A Phase 2 interventional study of Placebo and Baricitinib in Arthritis, Rheumatoid, sponsored by Eli Lilly and Company. Completed at 14 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 4th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
35 studies in Arthritis, Rheumatoid by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 20th largest by enrollment, is one of 5 that started in 2011, is one of 13 in phase 2, and was the 17th registered.
Eli Lilly and Company’s Arthritis, Rheumatoid studies by the year they started, since 2005.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 35 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b, outpatient, randomized, double-blinded (with a single-blind extension), placebo-controlled, dose-ranging, parallel-group study of baricitinib (LY3009104) in Japanese participants with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy. Baricitinib will be orally administered once a day with background methotrexate [6 to 16 milligrams (mg)/week] therapy for 12 weeks in the double-blind treatment period (1, 2, 4 or 8 mg/day, or placebo), and for 52 weeks in the single-blind extension period (4 or 8 mg/day).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64. The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).
Drug: Placebo · Drug: Methotrexate
1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64. The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).
Drug: Placebo · Drug: Baricitinib · Drug: Methotrexate
2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64. The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).
Drug: Baricitinib · Drug: Methotrexate
1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
Drug: Placebo · Drug: Baricitinib · Drug: Methotrexate
2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
Drug: Baricitinib · Drug: Methotrexate
Also known as: Sugar pill
Also known as: JAK1/JAK2 inhibitor, JAK1 inhibitor, JAK2 inhibitor, NCB028050, LY3009104
Also known as: JAK1/JAK2 inhibitor, JAK1 inhibitor, JAK2 inhibitor, NCB028050, LY3009104
Also known as: JAK1/JAK2 inhibitor, JAK1 inhibitor, JAK2 inhibitor, NCB028050, LY3009104
Administered orally as background therapy
Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .
ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) , Patient's Global Assessment of Disease Activity-VAS (PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR20 response = (number of ACR20 responders) /(number of participants treated) \* 100.
Time frame: 12 weeks
Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks
ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.
Time frame: Baseline up to 64 weeks
Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)
ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) \* 100.
Time frame: Baseline up to 12 weeks
Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)
ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR70 response=(number of ACR70 responders) / (number of participants treated) \* 100.
Time frame: Baseline up to 64 weeks
Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)
DAS modified included the DAS28 that consisted of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Baseline, 12 weeks
Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)
DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Baseline, 64 weeks
Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)
EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP ≤3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.
Time frame: Baseline up to 12 weeks
Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)
EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.
Time frame: Baseline up to 64 weeks
Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.
Time frame: Baseline up to 12 weeks
Mean Change in SDAI Responses up to 64 Weeks (Part B)
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.
Time frame: Baseline, 64 weeks
Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)
HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.
Time frame: Baseline, 12 weeks
Mean Change in HAQ-DI Responses up to 64 Weeks (Part B)
HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.
Time frame: Baseline, 64 weeks
Mean Value of ACR-N Response (Part A)
The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.
Time frame: Baseline up to 12 weeks
Mean Value of ACR-N Response (Part B)
The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.
Time frame: Baseline up to 64 weeks
Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)
DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) \* 100.
Time frame: Baseline up to 12 weeks
Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)
DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA-VAS on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(sqrt of TJC28)+0.28(sqrt of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS 28 remission) / (number of participants treated) \* 100.
Time frame: Baseline up to 64 weeks
Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100
Time frame: Baseline up to 12 weeks
Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100
Time frame: Baseline up to 64 weeks
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104
Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.
Time frame: Weeks (Wks) 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.
PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104
Time frame: Wks 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.
| Milestone | Part A: 1 mg Baricitinib (LY3009104) | Part A: 2 mg Baricitinib (LY3009104) | Part A: 4 mg Baricitinib (LY3009104) | Part A: 8 mg Baricitinib (LY3009104) | Part A: Placebo | Part:1 mg Baricitinib(LY3009104) / 4 mg Baricitinib(LY3009104) | Part B: 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30 | Part B: 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30 | Part B: Placebo /4 mg Baricitinib (LY3009104) | Part B: 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30 | Part B: 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY300 | Part B: 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30 | Part B: Placebo / 8 mg Baricitinib (LY3009104) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 24 | 24 | 24 | 24 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 24 | 24 | 24 | 24 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 23 | 24 | 23 | 24 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: 1 mg Baricitinib (LY3009104) | Part A: 2 mg Baricitinib (LY3009104) | Part A: 4 mg Baricitinib (LY3009104) | Part A: 8 mg Baricitinib (LY3009104) | Part A: Placebo | Part:1 mg Baricitinib(LY3009104) / 4 mg Baricitinib(LY3009104) | Part B: 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30 | Part B: 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30 | Part B: Placebo /4 mg Baricitinib (LY3009104) | Part B: 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30 | Part B: 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY300 | Part B: 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30 | Part B: Placebo / 8 mg Baricitinib (LY3009104) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 23 | 24 | 11 | 12 | 24 | 24 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 23 | 24 | 11 | 12 | 24 | 23 |
| Completed | 0 | 0 | 0 | 0 | 0 | 10 | 7 | 18 | 20 | 8 | 10 | 18 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 5 | 4 | 3 | 2 | 6 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 5 | 3 | 3 | 1 | 6 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 |
ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) , Patient's Global Assessment of Disease Activity-VAS (PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR20 response = (number of ACR20 responders) /(number of participants treated) \* 100.
| percentage of participants | Part A: Combined 4 mg and 8 mg Baricitinib (LY3009104) | Part A: Placebo |
|---|---|---|
| Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 . | 77 | 31 |
ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.
| percentage of participants | Combined 4 mg Baricitinib (LY3009104) (Part B) | Combined 8 mg Baricitinib (LY3009104) (Part B) |
|---|---|---|
| Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks | 66 | 73 |
ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) \* 100.
| percentage of participants | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A) | 13 | 29 | 29 | 21 | 0 |
ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR70 response=(number of ACR70 responders) / (number of participants treated) \* 100.
| percentage of participants | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B) | 37 | 34 |
DAS modified included the DAS28 that consisted of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| units on a scale | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP) | -1.52 ± 0.970 | -2.02 ± 1.072 | -2.09 ± 1.105 | -1.96 ± 0.947 | -0.60 ± 1.204 |
DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| units on a scale | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP) | -2.44 ± 1.152 | -2.48 ± 1.109 |
EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP ≤3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.
| percentage of participants | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A) | 83 | 88 | 92 | 92 | 47 |
EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.
| percentage of participants | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B) | 94 | 94 |
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.
| units on a scale | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A) | -13.11 ± 8.918 | -16.85 ± 9.517 | -18.17 ± 9.202 | -18.02 ± 8.293 | -4.54 ± 13.113 |
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.
| units on a scale | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Mean Change in SDAI Responses up to 64 Weeks (Part B) | -20.42 ± 9.671 | -21.33 ± 10.318 |
HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.
| units on a scale | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A) | -0.302 ± 0.3336 | -0.396 ± 0.4759 | -0.469 ± 0.3463 | -0.422 ± 0.3646 | -0.077 ± 0.3552 |
HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.
| units on a scale | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Mean Change in HAQ-DI Responses up to 64 Weeks (Part B) | -0.498 ± 0.4779 | -0.568 ± 0.6203 |
The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.
| percentage of responders | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Mean Value of ACR-N Response (Part A) | 28.76 ± 38.65 | 42.48 ± 39.52 | 45.17 ± 33.75 | 25.58 ± 130.02 | -9.98 ± 58.10 |
The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.
| percentage of responders | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Mean Value of ACR-N Response (Part B) | 61.14 ± 30.70 | 61.07 ± 33.22 |
DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) \* 100.
| percentage of participants | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A) | 33 | 33 | 42 | 50 | 22 |
DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA-VAS on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(sqrt of TJC28)+0.28(sqrt of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS 28 remission) / (number of participants treated) \* 100.
| percentage of participants | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B) | 66 | 66 |
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100
| percentage of participants | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A) | 4 | 29 | 17 | 17 | 8 |
The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100
| percentage of participants | Combined 4 mg Baricitinib (LY3009104) | Combined 8 mg Baricitinib (LY3009104) |
|---|---|---|
| Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B) | 39 | 39 |
Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.
| nanomoles*hour (nM*h) | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104 | 237 ± 28.8 | 525 ± 21 | 1020 ± 32.5 | 1900 ± 24.1 |
| nM | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) |
|---|---|---|---|---|
| PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104 | 35.7 ± 20.9 | 73.5 ± 22.5 | 147 ± 20.6 | 278 ± 21.7 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/49 (2%) | 26/49 (53.1%) |
| 1 mg Baricitinib (LY3009104) | — | 0/24 (0%) | 11/24 (45.8%) |
| 2 mg Baricitinib (LY3009104) | — | 1/24 (4.2%) | 12/24 (50%) |
| 4 mg Baricitinib (LY3009104) | — | 0/24 (0%) | 13/24 (54.2%) |
| 8 mg Baricitinib (LY3009104) | — | 1/24 (4.2%) | 17/24 (70.8%) |
| Placebo / 4 mg Baricitinib (LY3009104) | — | 1/24 (4.2%) | 21/24 (87.5%) |
| 1 mg Baricitinib (LY3009104) / 4mg Baricitinib (LY3009104) | — | 1/12 (8.3%) | 11/12 (91.7%) |
| 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104) | — | 3/12 (25%) | 11/12 (91.7%) |
| 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104) | — | 3/23 (13%) | 22/23 (95.7%) |
| Placebo /8 mg Baricitinib (LY3009104) | — | 2/23 (8.7%) | 23/23 (100%) |
| 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) | — | 2/11 (18.2%) | 11/11 (100%) |
| 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) | — | 2/12 (16.7%) | 12/12 (100%) |
| 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) | — | 6/24 (25%) | 23/24 (95.8%) |
| Event | Placebo | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo / 4 mg Baricitinib (LY3009104) | 1 mg Baricitinib (LY3009104) / 4mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104) | Placebo /8 mg Baricitinib (LY3009104) | 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Herpes zosterInfections and infestations | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 1/12 | 0/23 | 0/23 | 1/11 | 0/12 | 1/24 |
| FallInjury, poisoning and procedural complications | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 1/12 | 0/23 | 1/23 | 1/11 | 0/12 | 0/24 |
| Ulna fractureInjury, poisoning and procedural complications | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 0/12 | 0/23 | 0/23 | 1/11 | 0/12 | 0/24 |
| Blood creatine phosphokinase increasedInvestigations | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 0/12 | 0/23 | 0/23 | 1/11 | 0/12 | 0/24 |
| Cerebral haemorrhageNervous system disorders | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 0/12 | 0/23 | 0/23 | 1/11 | 0/12 | 0/24 |
| CataractEye disorders | 0/49 | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 0/12 | 0/12 | 0/23 | 0/23 | 0/11 | 1/12 | 1/24 |
| Large intestine polypGastrointestinal disorders | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 1/12 | 0/23 | 0/23 | 0/11 | 0/12 | 1/24 |
| Pancreatitis acuteGastrointestinal disorders | 0/49 | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 0/12 | 1/12 | 0/23 | 0/23 | 0/11 | 0/12 | 0/24 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 0/12 | 0/12 | 0/23 | 0/23 | 0/11 | 1/12 | 0/24 |
| PneumoniaInfections and infestations | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 1/12 | 0/12 | 0/23 | 0/23 | 0/11 | 0/12 | 0/24 |
| Event | Placebo | 1 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) | Placebo / 4 mg Baricitinib (LY3009104) | 1 mg Baricitinib (LY3009104) / 4mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104) | 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104) | Placebo /8 mg Baricitinib (LY3009104) | 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) | 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) | 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/49 | 2/24 | 2/24 | 2/24 | 2/24 | 4/24 | 5/12 | 6/12 | 7/23 | 9/23 | 1/11 | 1/12 | 5/24 |
| Dental cariesGastrointestinal disorders | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 0/12 | 1/23 | 0/23 | 2/11 | 0/12 | 0/24 |
| Blood creatine phosphokinase increasedInvestigations | 2/49 | 0/24 | 0/24 | 2/24 | 3/24 | 4/24 | 1/12 | 0/12 | 3/23 | 4/23 | 2/11 | 2/12 | 2/24 |
| HyperlipidaemiaMetabolism and nutrition disorders | 1/49 | 1/24 | 1/24 | 0/24 | 1/24 | 1/24 | 1/12 | 0/12 | 1/23 | 3/23 | 2/11 | 1/12 | 3/24 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 0/49 | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 1/12 | 0/12 | 1/23 | 1/23 | 2/11 | 1/12 | 0/24 |
| ConstipationGastrointestinal disorders | 1/49 | 0/24 | 0/24 | 0/24 | 0/24 | 2/24 | 2/12 | 1/12 | 0/23 | 2/23 | 1/11 | 1/12 | 1/24 |
| NauseaGastrointestinal disorders | 0/49 | 0/24 | 0/24 | 2/24 | 0/24 | 1/24 | 0/12 | 0/12 | 0/23 | 0/23 | 1/11 | 2/12 | 0/24 |
| Hepatic function abnormalHepatobiliary disorders | 0/49 | 0/24 | 3/24 | 0/24 | 3/24 | 1/24 | 2/12 | 1/12 | 3/23 | 0/23 | 0/11 | 0/12 | 2/24 |
| Herpes zosterInfections and infestations | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 1/12 | 2/12 | 1/23 | 1/23 | 1/11 | 0/12 | 2/24 |
| LacerationInjury, poisoning and procedural complications | 0/49 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/12 | 2/12 | 0/23 | 0/23 | 0/11 | 0/12 | 0/24 |
All randomized participants who received any amount of study treatment. All participants who completed Part A were re-randomized to 4 mg or 8 mg in Part B.
| Age, Continuous(years) | Part A: 1 mg Baricitinib (LY3009104) | Part A: 2 mg Baricitinib (LY3009104) | Part A: 4 mg Baricitinib (LY3009104) | Part A: 8 mg Baricitinib (LY3009104) | Part A: Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 52.7 ± 12.8 | 56.1 ± 11.5 | 57.5 ± 10.4 | 53.6 ± 11.3 | 51.1 ± 12.0 | 53.6 ± 11.8 |
| Sex: Female, Male(Participants) | Part A: 1 mg Baricitinib (LY3009104) | Part A: 2 mg Baricitinib (LY3009104) | Part A: 4 mg Baricitinib (LY3009104) | Part A: 8 mg Baricitinib (LY3009104) | Part A: Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 22 | 21 | 19 | 17 | 39 | 118 |
| Male | 2 | 3 | 5 | 7 | 10 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Part A: 1 mg Baricitinib (LY3009104) | Part A: 2 mg Baricitinib (LY3009104) | Part A: 4 mg Baricitinib (LY3009104) | Part A: 8 mg Baricitinib (LY3009104) | Part A: Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 24 | 24 | 24 | 24 | 49 | 145 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: 1 mg Baricitinib (LY3009104) | Part A: 2 mg Baricitinib (LY3009104) | Part A: 4 mg Baricitinib (LY3009104) | Part A: 8 mg Baricitinib (LY3009104) | Part A: Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 24 | 24 | 24 | 24 | 49 | 145 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A: 1 mg Baricitinib (LY3009104) | Part A: 2 mg Baricitinib (LY3009104) | Part A: 4 mg Baricitinib (LY3009104) | Part A: 8 mg Baricitinib (LY3009104) | Part A: Placebo | Total |
|---|---|---|---|---|---|---|
| Japan | 24 | 24 | 24 | 24 | 49 | 145 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Nov 2011, a primary completion of Nov 2012 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 6 years after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib